CellaVision AB Market Cap ($491.29 Million)
Market Cap & Net Worth: CellaVision AB (CEVI)
CellaVision AB market cap. CellaVision AB (ST:CEVI) has a market capitalization of $491.29 Million (Skr4.57 Billion) as of November 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #11991 globally and #196 in its home market, demonstrating a 12.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CellaVision AB's stock price Skr191.40 by its total outstanding shares 23851547 (23.85 Million). Also see cash flow conversion of CellaVision AB for how efficiently the company converts equity into cash flow.
CellaVision AB Market Cap History (2015–2026)
CellaVision AB market cap history from 2015 to 2026. Data shows growth from $164.81 Million to $491.29 Million (13.62% CAGR). Check today's stock price for CellaVision AB for real-time trading data and today's change.
CellaVision AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CellaVision AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CEVI shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.53x
CellaVision AB's market cap is 0.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.64x
CellaVision AB's market cap is 2.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $209.01 Million | $265.04 Million | $59.80 Million | 0.79x | 3.50x |
| 2017 | $352.76 Million | $309.31 Million | $69.72 Million | 1.14x | 5.06x |
| 2018 | $474.47 Million | $364.81 Million | $88.69 Million | 1.30x | 5.35x |
| 2019 | $795.33 Million | $461.77 Million | $99.17 Million | 1.72x | 8.02x |
| 2020 | $764.21 Million | $471.44 Million | $89.48 Million | 1.62x | 8.54x |
| 2021 | $811.13 Million | $565.55 Million | $125.34 Million | 1.43x | 6.47x |
| 2022 | $574.90 Million | $639.34 Million | $118.33 Million | 0.90x | 4.86x |
| 2023 | $538.76 Million | $677.29 Million | $130.31 Million | 0.80x | 4.13x |
| 2024 | $558.28 Million | $723.22 Million | $140.72 Million | 0.77x | 3.97x |
| 2025 | $403.50 Million | $758.97 Million | $153.08 Million | 0.53x | 2.64x |
Competitor Companies of CEVI by Market Capitalization
Companies near CellaVision AB in the global market cap rankings as of November 3, 2026. Also see total assets of CellaVision AB for a full breakdown of the balance sheet.
Key companies related to CellaVision AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $191.55 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $117.68 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #227 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $191.55 Billion | $110.16 |
| #204 | Stryker Corporation | NYSE:SYK | $117.68 Billion | $306.81 |
| #227 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $99.29 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of CellaVision AB (2015–2026)
Market capitalization of CellaVision AB from 2015 to today. Between 2015 and today, CellaVision AB's market cap moved from $164.81 Million to $ 491.29 Million, with a yearly change of 13.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr491.29 Million | +21.76% |
| 2025 | Skr403.50 Million | -27.72% |
| 2024 | Skr558.28 Million | +3.62% |
| 2023 | Skr538.76 Million | -6.29% |
| 2022 | Skr574.90 Million | -29.12% |
| 2021 | Skr811.13 Million | +6.14% |
| 2020 | Skr764.21 Million | -3.91% |
| 2019 | Skr795.33 Million | +67.63% |
| 2018 | Skr474.47 Million | +34.50% |
| 2017 | Skr352.76 Million | +68.78% |
| 2016 | Skr209.01 Million | +26.82% |
| 2015 | Skr164.81 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of CellaVision AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $491.29 Million USD |
| MoneyControl | $491.29 Million USD |
| MarketWatch | $491.29 Million USD |
| marketcap.company | $491.29 Million USD |
| Reuters | $491.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more